Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland
Open Access
- 11 December 2025
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (3) , e397-e407
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 20 references indexed in Scilit:
- ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemiaAnnals of Oncology, 2024
- ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 updateLeukemia, 2024
- Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaNature Communications, 2023
- Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemiaLeukemia, 2022
- Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary centereJHaem, 2021
- Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UKeJHaem, 2021
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendationsLeukemia, 2017
- ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaLeukemia, 2012
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011